Why Pfizer Needs a High-Growth Pipeline
Copyright 1995-2022 The Motley Fool. All rights reserved.
finance
2022-06-03 11:54:00

Pharmaceutical behemoth Pfizer (PFE 0.59%) has racked up successes duringÂ the COVID-19 outbreak, as the first to enter the market with a vaccine in December 2020 and a pill treatment in December 2021. Revenues have soared and look to remain strong through 2022. But the impressive growth of the past two years leaves Pfizer with the challenge of quickly generating new sources of revenue as pandemic sales tail off.

Image source: Getty Images.

Converting cash into products
Outside of the Covid space, Pfizer sells a number of megablockbusters such as blood-thinner Eliquis, breast-cancer drug Ibrance, pneumonia vaccine Prevnar, and arthritis treatment Xeljanz.
